6/30, 10:09 PM (Source: TeleTrader)
more TeleTrader news

Revive submits COVID-19 study application to FDA

Revive Therapeutics Ltd. announced on Tuesday that it submitted a request to the United States Food and Drug Administration (FDA) to approve a phase 3 study for its drug Bucillamine as a treatment for mild and moderate cases of COVID-19.

CEO Michael Frank said that the company "is preparing plans for initiating the Phase 3 study upon the IND becoming active by the US FDA, and looks forward to advancing Bucillamine as a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally."

The shares of the Canadian life sciences company ended 13.73% higher.

Breaking the News / VP